Eduarda P. Martins, Helena M. Figueiredo, Nuno Sousa, Bruno M. Costa
{"title":"Hijacking of neural circuits by malignant glioma: mechanistic insights and clinical implications","authors":"Eduarda P. Martins, Helena M. Figueiredo, Nuno Sousa, Bruno M. Costa","doi":"10.1016/j.jncc.2026.05.002","DOIUrl":"10.1016/j.jncc.2026.05.002","url":null,"abstract":"<div><div>Glioblastoma and other malignant gliomas are characterized by high heterogeneity that drives their aggressiveness and contributes to poor clinical outcomes. Understanding the mechanisms behind glioma malignancy, as well as the crosstalk between these tumors and their microenvironment, may hold transformative clinical relevance. Recent findings show that glioblastoma cells interact in bidirectional and multimodal crosstalk with the neuronal compartment of the microenvironment. While the knowledge on these complex interactions is still limited, it is now clear that dynamic communications include responses to neuronal activity-dependent molecules, synaptic signaling, and remodeling of neural circuits. Together, these direct and indirect dialogues promote glioma cells proliferation and invasion, effectively hijacking neuronal activity to fuel tumor aggressiveness. This review focuses on the bidirectional interaction between neurons and malignant glioma cells, highlighting its clinical relevance and potential to guide the development of novel precision therapies specifically targeting the glioma-neuron crosstalk.</div></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"6 5","pages":"Pages 459-471"},"PeriodicalIF":25.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149257879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Moonlighting function of extracellular GPX4 on immunogenicity of ferroptosis","authors":"Xin Wang, Dongqing Wang, Haitao Zhu","doi":"10.1016/j.jncc.2026.06.005","DOIUrl":"10.1016/j.jncc.2026.06.005","url":null,"abstract":"","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"6 5","pages":"Pages 453-454"},"PeriodicalIF":25.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149257881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Reply: When survival estimates mask underlying realities: Interpreting global prostate cancer survival disparities from registry data","authors":"Yuxin Zhou, Yixin Zou, Qiuming Shen, Zhuoying Li, Yuting Tan, Honglan Li, Yongbing Xiang","doi":"10.1016/j.jncc.2026.07.004","DOIUrl":"10.1016/j.jncc.2026.07.004","url":null,"abstract":"","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"6 5","pages":"Pages 451-452"},"PeriodicalIF":25.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149283982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"When survival estimates mask underlying realities: Interpreting global prostate cancer survival disparities from registry data","authors":"Xuefan Zeng","doi":"10.1016/j.jncc.2026.07.003","DOIUrl":"10.1016/j.jncc.2026.07.003","url":null,"abstract":"","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"6 5","pages":"Pages 449-450"},"PeriodicalIF":25.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149257873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jingwei Zhang, Md Imtiaz Khalil, Ranjan Mishra, Hao Li, Luigi Perelli, Robert A. Weinberg
{"title":"Corrigendum to “Intrinsic and extrinsic regulators of cancer dormancy and awakening” [Journal of the National Cancer Center 6 (2026) 211–218]","authors":"Jingwei Zhang, Md Imtiaz Khalil, Ranjan Mishra, Hao Li, Luigi Perelli, Robert A. Weinberg","doi":"10.1016/j.jncc.2026.08.001","DOIUrl":"10.1016/j.jncc.2026.08.001","url":null,"abstract":"","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"6 5","pages":"Page 512"},"PeriodicalIF":25.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149257874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Christos Adamopoulos, Kostas A. Papavassiliou, Athanasios G. Papavassiliou
{"title":"Reprogramming cancer at the tipping point","authors":"Christos Adamopoulos, Kostas A. Papavassiliou, Athanasios G. Papavassiliou","doi":"10.1016/j.jncc.2026.08.005","DOIUrl":"10.1016/j.jncc.2026.08.005","url":null,"abstract":"","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"6 5","pages":"Pages 455-458"},"PeriodicalIF":25.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149257880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Bingfeng Han, Rongshou Zheng, Hongmei Zeng, Shaoming Wang, Kexin Sun, Ru Chen, Li Li, Meicen Liu, Wanqing Chen, Wenqiang Wei, Jie He
{"title":"Premature cancer mortality in China based on cancer registry","authors":"Bingfeng Han, Rongshou Zheng, Hongmei Zeng, Shaoming Wang, Kexin Sun, Ru Chen, Li Li, Meicen Liu, Wanqing Chen, Wenqiang Wei, Jie He","doi":"10.1016/j.jncc.2026.07.006","DOIUrl":"10.1016/j.jncc.2026.07.006","url":null,"abstract":"<div><h3>Background</h3><div>The “Healthy China 2030” outline aims to reduce premature mortality from major non-communicable diseases by 30% by 2030 compared to the levels in 2015. In China, approximately 2.57 million cancer-related deaths occurred in 2022. Population-based cancer registries are crucial for assessing cancer burdens and guiding policy. The National Cancer Center (NCC) of China regularly collects cancer registry data, ensures quality control and reports the nationwide statistics on cancer mortality in China.</div></div><div><h3>Methods</h3><div>Data from 1073 cancer registries in China were submitted to the NCC in 2019. Quality control was conducted based on Chinese and international guidelines. Temporal trends in premature mortality rates from 2010 to 2019 were analyzed using data from 106 continuous cancer registries representing 8.85% of the Chinese population. Descriptive analysis, standardized mortality rates, and Joinpoint Regression were used to examine cancer-related deaths stratified by sex and area.</div></div><div><h3>Results</h3><div>In 2019, the premature mortality rate from cancer in China was 6.67%. Lung cancer had the highest premature mortality rate (1.87%), followed by liver cancer (1.15%). In South China, liver cancer had the highest premature mortality rate, while lung cancer led in other regions. Nasopharyngeal cancer had a higher premature mortality rate in South China. From 2010 to 2019, a significant decreasing trend of 1.9% per year was observed in premature cancer mortality, primarily due to declines in esophageal, stomach, and liver cancers.</div></div><div><h3>Conclusions</h3><div>Premature cancer mortality remains a significant issue in China, with lung cancer being the leading cause. Traditionally high-incidence digestive tract cancers in China still carried a substantial burden of premature mortality. Throughout the history of cancer prevention and control, there has been a notable decline in overall premature cancer mortality, particularly for cancers of the digestive tract. In the future, it is imperative to develop tailored screening, early diagnosis, and early treatment strategies for different cancers in order to achieve the goal of reducing premature cancer mortality and enhancing the health of the population.</div></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"6 5","pages":"Pages 482-489"},"PeriodicalIF":25.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149283924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yuhao Li, Yile You, Dequan Shi, Yiqiao Lv, Xin Zhan, Jieying Chen, Qing Yuan, Ming Liu, Ru Chen, Shengfeng Wang
{"title":"Socioeconomic inequalities in the epidemiological landscape of genitourinary cancers: a GLOBOCAN 2024 analysis","authors":"Yuhao Li, Yile You, Dequan Shi, Yiqiao Lv, Xin Zhan, Jieying Chen, Qing Yuan, Ming Liu, Ru Chen, Shengfeng Wang","doi":"10.1016/j.jncc.2026.09.009","DOIUrl":"10.1016/j.jncc.2026.09.009","url":null,"abstract":"<div><h3>Background</h3><div>Given the poor prognosis and marked geographic and socioeconomic inequalities in the burden of genitourinary cancers, updating the global epidemiological landscape is essential for informing region-specific and equity-oriented strategies.</div></div><div><h3>Methods</h3><div>Using GLOBOCAN 2024, we estimated age-standardized incidence (ASIR), mortality (ASMR), and 1−mortality-to-incidence ratio (1−M/I) for genitourinary cancers. Socioeconomic inequalities across Human Development Index (HDI) levels were quantified using the slope index of inequality (SII) and concentration index (ConI). We further decomposed factors contributing to these inequalities and estimated population attributable fractions (PAFs) for selected modifiable risk factors under specified counterfactual scenarios.</div></div><div><h3>Results</h3><div>In 2024, the global ASIR and ASMR of genitourinary cancers were 35.97 and 9.85 per 100,000, respectively, with a 1−M/I of 0.73. ASIRs were the highest in Northern America, Europe, and Australasia, whereas ASMRs peaked in Caribbean and African regions. ASIR and 1−M/I were substantially higher in very-high-HDI than low-HDI countries (ASIR: 71.07 vs 25.72 per 100,000; 1−M/I: 0.82 vs 0.40 per 100,000). Significant inequalities were observed for ASIR (SII: 62.15; ConI: 0.24) and 1−M/I (SII: 0.51; ConI: 0.14). Education, income, universal health coverage, and health expenditure were major contributors. Globally, Particulate Matter 2.5 showed the largest estimated PAFs for kidney (24.09%–28.53%) and bladder cancers (20.86%–24.52%) under alternative counterfactual exposure levels. The HIV-associated PAF for penile cancer was 2.82% globally and 10.64% in low-HDI countries, indicating marked heterogeneity across cancer types and HDI levels.</div></div><div><h3>Conclusions</h3><div>Genitourinary cancers exhibit geographic and socioeconomic inequalities, with pronounced heterogeneity in potentially attributable burden across modifiable risk factors and HDI levels. These findings support context-specific prevention and health-system strategies.</div></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"6 5","pages":"Pages 490-501"},"PeriodicalIF":25.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149283925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rongshou Zheng, Kexin Sun, Bingfeng Han, Li Li, Ru Chen, Shaoming Wang, Meicen Liu, Hongmei Zeng, Wanqing Chen, Wenqiang Wei, Jie He
{"title":"Cancer incidence and mortality in China, 2024","authors":"Rongshou Zheng, Kexin Sun, Bingfeng Han, Li Li, Ru Chen, Shaoming Wang, Meicen Liu, Hongmei Zeng, Wanqing Chen, Wenqiang Wei, Jie He","doi":"10.1016/j.jncc.2025.10.003","DOIUrl":"10.1016/j.jncc.2025.10.003","url":null,"abstract":"<div><h3>Background</h3><div>Cancer remains a major public health issue globally, with a growing burden due to population aging and lifestyle changes. This study provides the estimates of cancer burden in China for 2024.</div></div><div><h3>Methods</h3><div>Cancer data of year 2019 from 919 population-based cancer registries across China submitted to the National Cancer Center were selected, with 106 registries providing continuous data from 2010 to 2019 being used to predict the burden of cancer in 2024. The Segi’s world standard population was used to estimate the age-standardized rates. Joinpoint regression analysis was used to evaluate the trends from 2000 to 2019 by calculating the annual percentage changes (APC) and average annual percentage changes (AAPC).</div></div><div><h3>Results</h3><div>In 2024, an estimated 5,150,000 new cancer cases and 2,580,000 cancer deaths occurred in China. The age-standardized incidence rate (ASIR) was 207.70 per 100,000 population and the age-standardized mortality rate (ASMR) was 90.90 per 100,000 population. Lung cancer was the most diagnosed cancer, followed by thyroid, colorectal, breast, and liver cancers. Collectively these top five cancers accounted for 59.13 % of all new cases. The leading cause of cancer death was lung cancer, followed by liver cancer, colorectal cancer, stomach cancer, and esophageal cancer, which together comprised of 66.75 % of all cancer deaths. The age-specific incidence rates increased with age for most cancer sites in men, but for cancers of breast, thyroid, ovarian, and cervix in women, the rates increased significantly in young and middle ages. The age-specific mortality rate increased with age and showed a higher level in men than in women. From 2000 to 2019, the ASIR for all cancers combined increased significantly (AAPC = 1.6 %), while the ASMR decreased (AAPC = −1.4 %). Cancers of the esophagus, stomach, and liver showed declining incidence and mortality trends, whereas thyroid, prostate, and cervical cancers exhibited significant increases in incidence.</div></div><div><h3>Conclusions</h3><div>The cancer burden in China continued to be substantial, characterized by a coexistence of cancer patterns of both developing and developed countries. The results highlight the necessity for targeted policies within the “Healthy China 2030\" initiative to address sex and age disparities, as well as evolving cancer patterns.</div></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"6 5","pages":"Pages 472-481"},"PeriodicalIF":25.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149257872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Xiaomin Liu, Wenlong Zheng, Yuting Ji, Jingjing Li, Yunmeng Zhang, Kexin Chen, Fengju Song, Lei Yang, Yubei Huang
{"title":"Burden, trends, and projections of prostate cancer: global cancer statistics (GLOBOCAN) estimates for 2024 and 2022","authors":"Xiaomin Liu, Wenlong Zheng, Yuting Ji, Jingjing Li, Yunmeng Zhang, Kexin Chen, Fengju Song, Lei Yang, Yubei Huang","doi":"10.1016/j.jncc.2026.09.008","DOIUrl":"10.1016/j.jncc.2026.09.008","url":null,"abstract":"<div><h3>Objective</h3><div>Prostate cancer remains a major health burden with substantial epidemiological disparities. Integrating updated estimates is essential for understanding evolving disease patterns and guiding future health policies.</div></div><div><h3>Methods</h3><div>Using GLOBOCAN 2024, we systematically analyzed prostate cancer incidence and mortality across 186 countries, stratified by United Nations regions, age at onset (<50 vs. ≥50 years), and Human Development Index (HDI). Temporal trends were assessed using estimated annual percentage change, and future burden was projected to 2050 assuming constant age-specific rates. The mortality-to-incidence ratio (MIR) was calculated as a surrogate for health-system performance.</div></div><div><h3>Results</h3><div>In 2024, an estimated 1,546,112 new cases (ASIR 29.30/100,000) and 419,849 deaths (ASMR 7.50/100,000) occurred globally, an increase of 5% from 2022. North America had the highest incidence (ASIR 80.82/100,000), whereas mortality was highest in the Caribbean (28.55/100,000) and Western Africa (24.60/100,000). Very-high-HDI countries had the highest incidence but favourable MIRs (∼0.13 in U.S.), whereas low-HDI countries had MIRs of ∼0.62 (Nigeria), signalling major diagnostic and therapeutic gaps. Temporal trends showed rising incidence in Africa and Asia, with declining mortality in most regions except Africa; early-onset mortality increased in Asia and Oceania. By 2050, global cases and deaths are projected to rise substantially, with the largest proportional increases in Africa; early-onset cases will decline in Eastern Asia, South America, and most of Europe.</div></div><div><h3>Conclusions</h3><div>The global prostate cancer burden is shifting towards transitioning countries, where low MIRs reveal major gaps in early detection. Prioritising risk-stratified screening and strengthening health-system infrastructure in resource-limited settings are urgently needed to guide global policy.</div></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"6 5","pages":"Pages 502-511"},"PeriodicalIF":25.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149257875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}